ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
IOL Chemicals and Pharmaceuticals Ltd will expand Ibuprofen capacity by 6,000 MTPA. The project, requiring a ₹350 Crore investment, is expected to be commercialized by December 2027.
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
IOL Chemicals and Pharmaceuticals Limited held its 39th Annual General Meeting on September 2, 2026. Members approved the audited financial statements and director re-appointment with requisite majority.
IOL delivers a strong Q1FY27 beat driven by a 67% revenue jump in non-ibuprofen APIs and improved operating leverage.
IOLCP reported strong Q1 FY27 results with Revenue at ₹756.3 Cr (up 37.1% YoY) and PAT at ₹64.5 Cr (up 89.9% YoY). The company is strategically shifting towards high-value non-Ibuprofen APIs.
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹756.3 Cr (+37.1% YoY) and net profit of ₹64.4 Cr (+90.0% YoY) for Q1 FY27.
IOL reported record Q4 FY26 revenue of ₹619cr (up 17.4% YoY) and PAT of ₹53cr (up 68% YoY), driven by diversification into non-Ibuprofen APIs and improved chemical segment realization.
IOL reported strong growth in Q4 FY26 with revenue up 17.4% YoY. The company is strategically shifting towards high-value non-Ibuprofen APIs and expanding specialty chemical capacities.
IOL Chemicals and Pharmaceuticals Ltd reported revenue from operations of ₹619.5 Cr (+17.4% YoY) and net profit of ₹53.2 Cr (+69.4% YoY) for Q4 FY26.